First off I do not believe that the company cares about retail shareholders or for that matter any shareholders at this point in time. The company has $150 million in the bank and they have no immediate need for cash so whether the price is at 5or 50 it really doesn’t matter. Secondly, if we are forced to go out and do new trials for Alzheimer’s and Rett I truly believe that anavex will not be doing these trials, and that they will be done with by a partner. That is where the major cash will come from to complete a large Alzheimer’s study. So with that said, and our stock floundering in the fives now I truly believe that if we do not get at least a phase 4 trial in Alzheimer’s with approval, then the partner will complete the p3 trial and our stock will rise significantly based on that deal. It would be great if we see a positive stance come from the FDA and allow the company to submit an NDA for approval of blarcamisine for Alzheimer’s the fallback is not so bad either. Allowing us to submit an NDA is obviously the better path and the quickest path to a fair market value for the company. But if we get our partnership, and must do another phase 3, that is not the end of the world either, as we will be propelled, much higher based on this partnership. And it obviously Solidifies our standings in the world of Alzheimer’s research.